Drug Trial Radar · NCT07280936
A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
76
Actual
Start
Jan 5, 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation study (MAD) in obese patients.
Conditions
- Obesity
- Overweight
Interventions
SHR-2906 InjectionDrug
SHR-2906 injection, in different doses.
SHR-2906 Injection PlaceboDrug
SHR-2906 injection placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs).Time frame: Part1: 57 days; Part2: 113 days.
- Incidence of serious adverse events (SAEs).Time frame: Part1: 57 days; Part2: 113 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.